Stockreport

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B [Yahoo! Fin...

Arbutus Biopharma Corporation  (ABUS) 
Last arbutus biopharma corporation earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.arbutusbio.com/node/5806
PDF of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the IM-PROVE II trial, conducted in partners [Read more]